







Cancer prevalence in Switzerland: Hodgkin Lymphoma

ICD-10: C81





Women



Years since Diagnosis

 0 to <1	 1 to <2
 2 to <5	 5 to <10

Technical note:

Cancer prevalence is defined as the number of persons alive at the date of reference and who have previously been diagnosed with cancer. Primary malignant cancer diagnoses were extracted from the National Cancer Dataset managed by the National Agency for Cancer Registration (NACR), hosted by the Foundation National Institute for Cancer Epidemiology and Registration (NICER), for the purpose of national cancer reporting in Switzerland. Data from 12 Swiss cantons registering cancer cases with diagnosis year at least 2000 up to 2018, and providing vital-status follow-up until 2018, were eligible for this study. In subjects with multiple primary malignant cancers, the first occurring diagnosis in each cancer reporting group was counted. Prevalence projections for reference dates after 31.12.2018 are based on predictions of incidence rates and survival proportions, and population sizes (2019 - 2025). Some cancer types have not been projected to 2025 due to data scarcity. The observed and projected number of prevalent subjects was extrapolated to the country as a whole and rounded to the nearest integer value.

Contact information in case of questions or requests for further technical details:

National Agency for Cancer Registration (NACR)
c/o Foundation National Institute for Cancer Epidemiology and Registration (NICER)
c/o University of Zurich
Hirschengraben 82
CH 8001 Zurich
Switzerland

P +41 44 634 53 74
F +41 44 634 54 44
nacr@nicer.org

Zurich, 24.9.2021